Summary of Study ST003661

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002271. The data can be accessed directly via it's Project DOI: 10.21228/M82V6D This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST003661
Study TitleLipidomics facilitates the discovery of diagnostic biomarkers in patients with chronic total occlusion during the perioperative period
Study SummaryChronic total occlusion (CTO) is a subtype of cardiovascular disease associated with high mortality and an increased risk of ventricular arrhythmia. This study aimed to investigate lipidomic changes in CTO patients undergoing percutaneous coronary intervention (PCI) using a tandem-lipidomic strategy. We first applied a global lipidomic approach to identify the serum lipidomes of CTO-PCI patients during the perioperative period, successfully separating and identifying over 1,500 lipids. Based on these results, a Multiple Reaction Monitoring (MRM) quantification method was developed and employed for targeted lipidomic analysis. Using a high-throughput MRM tandem liquid chromatography-mass spectrometry approach, 613 lipids were successfully quantified in CTO-PCI patients and control donors. PA 18:2/11:0 emerged as a potential biomarker for distinguishing CTO patients from those suspected of having the condition. Notably, patients with different prognostic outcomes exhibited significantly distinct serum lipidomes in both pre- and post-CTO-PCI samples. This finding suggests that lipidomic data hold significant potential not only for monitoring postoperative prognosis but also for predicting surgical outcomes
Institute
Zhongshan Hospital Fudan University
Last NameWang
First NameZhenxin
Address136 Yi Xue Yuan Road
Emailwang.zhenxin@zs-hospital.sh.cn
Phone+8618817976583
Submit Date2024-12-04
Num Groups4
Total Subjects63
Raw Data AvailableYes
Raw Data File Type(s)wiff
Analysis Type DetailLC-MS
Release Date2025-01-20
Release Version1
Zhenxin Wang Zhenxin Wang
https://dx.doi.org/10.21228/M82V6D
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Degree of coronary artery occlusion Operation
SA400956CON8control control
SA400957shotgun-CON 3control control
SA400958CON1control control
SA400959CON2control control
SA400960CON3control control
SA400961CON4control control
SA400962CON5control control
SA400963CON6control control
SA400964CON7control control
SA400965CON10control control
SA400966CON9control control
SA400967CON11control control
SA400968CON12control control
SA400969CON13control control
SA400970CON14control control
SA400971CON15control control
SA400972CON16control control
SA400973CON17control control
SA400974CON18control control
SA400975CON19control control
SA400976CON20control control
SA400977shotgun-CON 2control control
SA400978shotgun-CON 1control control
SA400916CTO-PCI3Disease group 24 hours after CTO-PCI operation
SA400917CTO-PCI7Disease group 24 hours after CTO-PCI operation
SA400918CTO-PCI6Disease group 24 hours after CTO-PCI operation
SA400919CTO-PCI5Disease group 24 hours after CTO-PCI operation
SA400920CTO-PCI4Disease group 24 hours after CTO-PCI operation
SA400921shotgun-POST-24H1Disease group 24 hours after CTO-PCI operation
SA400922shotgun-POST-24H2Disease group 24 hours after CTO-PCI operation
SA400923shotgun-POST-24H3Disease group 24 hours after CTO-PCI operation
SA400924CTO-PCI1Disease group 24 hours after CTO-PCI operation
SA400925CTO-PCI2Disease group 24 hours after CTO-PCI operation
SA400926shotgun-POST-72H3Disease group 72 hours after CTO-PCI operation
SA400927shotgun-POST-72H2Disease group 72 hours after CTO-PCI operation
SA400928shotgun-POST-72H1Disease group 72 hours after CTO-PCI operation
SA400929CTO15Disease group pre-operation
SA400930CTO7Disease group pre-operation
SA400931CTO8Disease group pre-operation
SA400932CTO9Disease group pre-operation
SA400933CTO10Disease group pre-operation
SA400934CTO11Disease group pre-operation
SA400935CTO12Disease group pre-operation
SA400936CTO13Disease group pre-operation
SA400937CTO14Disease group pre-operation
SA400938CTO22Disease group pre-operation
SA400939CTO16Disease group pre-operation
SA400940CTO17Disease group pre-operation
SA400941CTO18Disease group pre-operation
SA400942CTO19Disease group pre-operation
SA400943CTO20Disease group pre-operation
SA400944CTO21Disease group pre-operation
SA400945CTO5Disease group pre-operation
SA400946CTO23Disease group pre-operation
SA400947CTO24Disease group pre-operation
SA400948CTO6Disease group pre-operation
SA400949CTO1Disease group pre-operation
SA400950CTO4Disease group pre-operation
SA400951CTO2Disease group pre-operation
SA400952shotgun-CTO 1Disease group pre-operation
SA400953shotgun-CTO 2Disease group pre-operation
SA400954shotgun-CTO 3Disease group pre-operation
SA400955CTO3Disease group pre-operation
Showing results 1 to 63 of 63
  logo